Genelux Corporation – NASDAQ:GNLX
Genelux stock price today
$3.43
+0.95
+38.31%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 9 hours
Genelux stock price monthly change
+5.53%
month
Genelux stock price quarterly change
+5.53%
quarter
Genelux stock price yearly change
-83.19%
year
Genelux key metrics
Market Cap | 76.32M |
Enterprise value | 296.35M |
P/E | -141.24 |
EV/Sales | 26.77 |
EV/EBITDA | -36.21 |
Price/Sales | 24.43 |
Price/Book | -7.55 |
PEG ratio | -7.95 |
EPS | -0.97 |
Revenue | N/A |
EBITDA | -24.84M |
Income | -25.78M |
Revenue Q/Q | -95.29% |
Revenue Y/Y | -86.90% |
Profit margin | -106.87% |
Oper. margin | -83.81% |
Gross margin | 0% |
EBIT margin | -83.81% |
EBITDA margin | N/A |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeGenelux stock price history
Genelux stock forecast
Genelux financial statements
| Jun 2023 | 0 | -5.82M | |
|---|---|---|---|
| Sep 2023 | 0 | -5.34M | |
| Dec 2023 | 1.46M | -6.76M | -462.23% |
| Mar 2024 | 8K | -7.85M | -98125% |
| Sep 2025 | 0 | -6.16M | |
|---|---|---|---|
| Oct 2025 | 5.23K | -4.83M | -92302.37% |
| Dec 2025 | 0 | -5.76M | |
| Dec 2025 | 4.87K | -4.83M | -99076.51% |
Analysts Price target
Financials & Ratios estimates
| 2024-03-29 | -0.21 | -0.25 |
|---|---|---|
| 2024-05-09 | -0.23 | -0.29 |
| 2024-07-05 | -0.21 | -0.29 |
| Jun 2023 | 31363000 | 9.10M | 29.04% |
|---|---|---|---|
| Sep 2023 | 34072000 | 10.04M | 29.48% |
| Dec 2023 | 27893000 | 8.42M | 30.19% |
| Mar 2024 | 24676000 | 9.59M | 38.87% |
| Jun 2023 | -5.41M | -396K | 22.61M |
|---|---|---|---|
| Sep 2023 | -3.35M | -277K | 6.36M |
| Dec 2023 | -6.91M | -13.94M | 401K |
| Mar 2024 | -4.35M | -1.69M | 688K |
Genelux alternative data
| Aug 2023 | 15 |
|---|---|
| Sep 2023 | 20 |
| Oct 2023 | 20 |
| Nov 2023 | 20 |
| Dec 2023 | 22 |
| Jan 2024 | 22 |
| Feb 2024 | 22 |
| Mar 2024 | 22 |
| Apr 2024 | 23 |
| May 2024 | 23 |
| Jun 2024 | 23 |
| Jul 2024 | 23 |
Genelux other data
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Apr 2024 | 0 | 142753 |
| May 2024 | 536000 | 88971 |
| Jun 2024 | 0 | 17306 |
| Aug 2024 | 0 | 357182 |
| Sep 2024 | 0 | 184548 |
| Dec 2024 | 0 | 25228 |
-
What's the price of Genelux stock today?
One share of Genelux stock can currently be purchased for approximately $3.43.
-
When is Genelux's next earnings date?
Unfortunately, Genelux's (GNLX) next earnings date is currently unknown.
-
Does Genelux pay dividends?
No, Genelux does not pay dividends.
-
How much money does Genelux make?
Genelux has a market capitalization of 76.32M and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 98.46% to 170K US dollars. Genelux made a loss 28.3M US dollars in net income (profit) last year or -$0.29 on an earnings per share basis.
-
What is Genelux's stock symbol?
Genelux Corporation is traded on the NASDAQ under the ticker symbol "GNLX".
-
What is Genelux's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Genelux?
Shares of Genelux can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
How many employees does Genelux have?
As Jul 2024, Genelux employs 23 workers.
-
When Genelux went public?
Genelux Corporation is publicly traded company for more then 2 years since IPO on 26 Jan 2023.
-
What is Genelux's official website?
The official website for Genelux is genelux.com.
-
Where are Genelux's headquarters?
Genelux is headquartered at 2625 Townsgate Road, Westlake Village, CA.
-
How can i contact Genelux?
Genelux's mailing address is 2625 Townsgate Road, Westlake Village, CA and company can be reached via phone at 858 483 0024.
Genelux company profile:
Genelux Corporation
genelux.comExchange:
NASDAQ
Full time employees:
24
Industry:
Biotechnology
Sector:
Healthcare
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary, modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small-cell lung cancer. The company is also developing V2ACT Immunotherapy for the treatment of pancreatic cancer; and V-VET1 to treat hematologic and solid cancer. The company was incorporated in 2001 and is headquartered in Westlake Village, California.
2625 Townsgate Road
Westlake Village, CA 91361
Westlake Village, CA 91361
CIK: 0001231457
ISIN: US36870H1032
:
